Numares AG

Numares Health is a precision diagnostics company specializing in AI-enabled biomarker tests using nuclear magnetic resonance (NMR) spectroscopy and machine learning. Founded as a spin-off from Regensburg University, the company develops in vitro diagnostic (IVD) tests for metabolic dysfunction-related diseases, including chronic kidney, liver, and cardiac conditions. The flagship AXINON® System is an FDA-cleared platform that quantifies multiple biomarkers from a single serum sample using multiplex metabolomics. Current product portfolio includes AXINON® LDL-p Test System (cardiovascular risk assessment, FDA-cleared in US and CE-marked in EU), AXINON® GFR(NMR) (kidney function assessment using novel biomarkers valine and myo-inositol alongside creatinine and cystatin C, CE-marked), AXINON® lipoFIT® (cardiovascular risk assessment, CE-marked), and AXINON® HCC(NMR) (liver cancer detection, in development). The company operates from Houston, Texas and Regensburg, Germany, collaborating with institutions such as Mayo Clinic and Oxford University to advance clinical integration of metabolomics-based diagnostics.